Survival of skin cancer stem cells requires the Ezh2 polycomb group protein

Gautam Adhikary, Daniel Grun, Sivaprakasam Balasubramanian, Candace Kerr, Jennifer M. Huang, Richard L. Eckert

Research output: Contribution to journalArticle

Abstract

Polycomb group proteins, including Ezh2, are important candidate stem cell maintenance proteins in epidermal squamous cell carcinoma. We previously showed that epidermal cancer stem cells (ECS cells) represent a minority of cells in tumors, are highly enriched in Ezh2 and drive aggressive tumor formation. We now show that Ezh2 is required for ECS cell survival, migration, invasion and tumor formation and that this is associated with increased histone H3 trimethylation on lysine 27, a mark of Ezh2 action. We also show that Ezh2 knockdown or treatment with Ezh2 inhibitors, GSK126 or EPZ-6438, reduces Ezh2 level and activity, leading to reduced ECS cell spheroid formation, migration, invasion and tumor growth. These studies indicate that epidermal squamous cell carcinoma cells contain a subpopulation of cancer stem (tumor-initiating) cells that are enriched in Ezh2, that Ezh2 is required for optimal ECS cell survival and tumor formation and that treatment with Ezh2 inhibitors may be a strategy for reducing ECS cell survival and suppressing tumor formation.

Original languageEnglish (US)
Pages (from-to)800-810
Number of pages11
JournalCarcinogenesis
Volume36
Issue number7
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Polycomb-Group Proteins
Neoplastic Stem Cells
Skin Neoplasms
Neoplasms
Cell Survival
Squamous Cell Carcinoma
Histones
Lysine
Cell Movement
Stem Cells
Maintenance

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

Adhikary, G., Grun, D., Balasubramanian, S., Kerr, C., Huang, J. M., & Eckert, R. L. (2015). Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Carcinogenesis, 36(7), 800-810. https://doi.org/10.1093/carcin/bgv064

Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. / Adhikary, Gautam; Grun, Daniel; Balasubramanian, Sivaprakasam; Kerr, Candace; Huang, Jennifer M.; Eckert, Richard L.

In: Carcinogenesis, Vol. 36, No. 7, 2015, p. 800-810.

Research output: Contribution to journalArticle

Adhikary, G, Grun, D, Balasubramanian, S, Kerr, C, Huang, JM & Eckert, RL 2015, 'Survival of skin cancer stem cells requires the Ezh2 polycomb group protein', Carcinogenesis, vol. 36, no. 7, pp. 800-810. https://doi.org/10.1093/carcin/bgv064
Adhikary G, Grun D, Balasubramanian S, Kerr C, Huang JM, Eckert RL. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Carcinogenesis. 2015;36(7):800-810. https://doi.org/10.1093/carcin/bgv064
Adhikary, Gautam ; Grun, Daniel ; Balasubramanian, Sivaprakasam ; Kerr, Candace ; Huang, Jennifer M. ; Eckert, Richard L. / Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. In: Carcinogenesis. 2015 ; Vol. 36, No. 7. pp. 800-810.
@article{265307a1d2584b80b5e1ca950420c43a,
title = "Survival of skin cancer stem cells requires the Ezh2 polycomb group protein",
abstract = "Polycomb group proteins, including Ezh2, are important candidate stem cell maintenance proteins in epidermal squamous cell carcinoma. We previously showed that epidermal cancer stem cells (ECS cells) represent a minority of cells in tumors, are highly enriched in Ezh2 and drive aggressive tumor formation. We now show that Ezh2 is required for ECS cell survival, migration, invasion and tumor formation and that this is associated with increased histone H3 trimethylation on lysine 27, a mark of Ezh2 action. We also show that Ezh2 knockdown or treatment with Ezh2 inhibitors, GSK126 or EPZ-6438, reduces Ezh2 level and activity, leading to reduced ECS cell spheroid formation, migration, invasion and tumor growth. These studies indicate that epidermal squamous cell carcinoma cells contain a subpopulation of cancer stem (tumor-initiating) cells that are enriched in Ezh2, that Ezh2 is required for optimal ECS cell survival and tumor formation and that treatment with Ezh2 inhibitors may be a strategy for reducing ECS cell survival and suppressing tumor formation.",
author = "Gautam Adhikary and Daniel Grun and Sivaprakasam Balasubramanian and Candace Kerr and Huang, {Jennifer M.} and Eckert, {Richard L.}",
year = "2015",
doi = "10.1093/carcin/bgv064",
language = "English (US)",
volume = "36",
pages = "800--810",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Survival of skin cancer stem cells requires the Ezh2 polycomb group protein

AU - Adhikary, Gautam

AU - Grun, Daniel

AU - Balasubramanian, Sivaprakasam

AU - Kerr, Candace

AU - Huang, Jennifer M.

AU - Eckert, Richard L.

PY - 2015

Y1 - 2015

N2 - Polycomb group proteins, including Ezh2, are important candidate stem cell maintenance proteins in epidermal squamous cell carcinoma. We previously showed that epidermal cancer stem cells (ECS cells) represent a minority of cells in tumors, are highly enriched in Ezh2 and drive aggressive tumor formation. We now show that Ezh2 is required for ECS cell survival, migration, invasion and tumor formation and that this is associated with increased histone H3 trimethylation on lysine 27, a mark of Ezh2 action. We also show that Ezh2 knockdown or treatment with Ezh2 inhibitors, GSK126 or EPZ-6438, reduces Ezh2 level and activity, leading to reduced ECS cell spheroid formation, migration, invasion and tumor growth. These studies indicate that epidermal squamous cell carcinoma cells contain a subpopulation of cancer stem (tumor-initiating) cells that are enriched in Ezh2, that Ezh2 is required for optimal ECS cell survival and tumor formation and that treatment with Ezh2 inhibitors may be a strategy for reducing ECS cell survival and suppressing tumor formation.

AB - Polycomb group proteins, including Ezh2, are important candidate stem cell maintenance proteins in epidermal squamous cell carcinoma. We previously showed that epidermal cancer stem cells (ECS cells) represent a minority of cells in tumors, are highly enriched in Ezh2 and drive aggressive tumor formation. We now show that Ezh2 is required for ECS cell survival, migration, invasion and tumor formation and that this is associated with increased histone H3 trimethylation on lysine 27, a mark of Ezh2 action. We also show that Ezh2 knockdown or treatment with Ezh2 inhibitors, GSK126 or EPZ-6438, reduces Ezh2 level and activity, leading to reduced ECS cell spheroid formation, migration, invasion and tumor growth. These studies indicate that epidermal squamous cell carcinoma cells contain a subpopulation of cancer stem (tumor-initiating) cells that are enriched in Ezh2, that Ezh2 is required for optimal ECS cell survival and tumor formation and that treatment with Ezh2 inhibitors may be a strategy for reducing ECS cell survival and suppressing tumor formation.

UR - http://www.scopus.com/inward/record.url?scp=84941644621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941644621&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgv064

DO - 10.1093/carcin/bgv064

M3 - Article

C2 - 25969142

AN - SCOPUS:84941644621

VL - 36

SP - 800

EP - 810

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 7

ER -